HeartStat Technology, Inc. (OTC: HSTA)

Market

Heart STAT preventive monitoring enables early intervention to avoid vital
patient complications that occur with BP and pulse oximeter devices:

· Brain Neuropsychiatric Dysfunction for 50% of surgery patients
with cardiovascular disease. Target: Anesthesiologists & surgeons.

· Septic Shock of critical care patients; reported 750,000 cases
with 29% mortality annually. Target: Critical care providers

· Cardiogenic Shock of bleeding. Target: Surgeons, Recovery & ER;

· Heart Attack warning and Congestive Heart Failure (CHF)
management and early discharge. Target: Heart care providers.

These conditions cause approximately 60 unexpected patient deaths and
$6M of costs annually in average size 200-bed hospitals. The available hospital market for the Company's monitors and sensors initially is $1 billion, in contrast to the present market of $2.1 billion. The Company's market will increase to $1.9 billion when it later supplies modules and multiparameter monitor systems.

Strategies

The Company will focus on the operating room and critical care markets, asserting the benefits of (i) flow monitoring to prevent septic and cardiogenic shock and for managing congestive heart failure;
(ii) surgery perfusion monitoring for brain safety and for reliable
POX monitoring; and (iii) biophysic monitoring to avoid heart attacks.

Key strategy elements are:

· HIGH MARGINS AND GROWTH ... to be facilitated by the unique low-cost
design and price competitiveness of the Company's monitor and sensors.

· AVOIDANCE OF CAPITAL BUDGET delays ... by supplying approximately half
of our systems pursuant to sensor purchases from hospital operating funds.

· TAPPING existing CAPITAL budgets ... substituting price-competitive CNBP
model sales as "platform" for upgrade to flow monitoring with sensor contracts.

· SYSTEM COMMONALITY syNERGy ... all product models based on the same
low-cost system for substantial manufacturing and distribution efficiencies.

· Malpractice RISK avoidance ... a major user impetus; to be stimulated with the same dissemination tactics that accelerated POX acceptance and standardization.

· Capital efficient marketing ... the Company's foolproof system
enables low-cost regional dealer marketing and transition to direct selling.

(In the Company's markets, marketing is direct or by national or regional dealers)

· franchise CREATION ... the Company's proprietary sensing system
and patent position is expected to create a strong market position.

Management

The CEO and principal inventor has 23 years experience as CEO and medical device technical management, was management consultant for Booz, Allen & Hamilton and 10 years of specialized experience in governance, accounting and financial operations controls. The Company marketing, technical and operational managers have in-depth experience at major firms and specializations in software, cardiovascular physiology, system design, physics, and mathematics.

COMPETENCE ... and willingness to adapt, learn and to surround ourselves with top talent.

James R. Hudson

Chief Executive Officer & Director

James R. Hudson has been promoted to Interim Chief Executive Officer since October 15, 2004. Prior to this Mr. Hudson served as interim President since March 18, 2004. Since November 1986, he has been the chief executive officer of Hudson Medical Systems Limited, Ridgetown, Ontario, Canada, a specialty products distribution company he founded in 1986 that supplies medical device products to acute care hospitals throughout Canada. He has over forty years of experience in the health care industry. He served as distributor of the Company's predecessor CNBP blood pressure monitor. From 1983 to 1986, he was general manager of the Cardiovascular Division of Gould Electronics, Canada. In 1978 he founded and was chief executive officer of Northern Medical Industries Limited, Mississauga, Ontario, Canada, a company that went public in 1979. In 1970 he became chief executive officer and took public Medicraft Limited in Rexdale, Ontario. Both Northern Medical and Medicraft were engaged in the manufacture and sale of intubation products. Previously, he was regional manager responsible for sales development at C.R. Bard Inc., and was salesman for Ames Diagnostics, a division of Miles Laboratories.

Ted W. Russell

President & Director

Mr. Russell invented the HeartSTAT technology and for twenty years has been managing its product development and business activities. Some of this ran parallel with his twenty years experience as CEO of computer and medical device companies that provided corporate governance experience as board chairman and CFO (including two public companies, one which he took public). Earlier, he was Director of Corporate Development, National Medical Care Inc; was Vice President in Corporate Finance, Smith Barney Harris Upham Inc. and for Smith Barney Capital Corporation; and was senior general management consultant for Booz, Allen & Hamilton, for which he performed and managed engagements with top managements of General Electric, Federal Express and WT Grant. Earlier he was CEO and Board Chairman of a minority-owned Memorex affiliate with over $200 million revenues; previously at Memorex he was a task-force manager responsible for a computer products end user marketing rollout. Prior to that he held financial controllership and engineering positions at Eastman Kodak Company. He received and has pending several patents for medical devices. He received a BS Industrial Engineering degree from University of Michigan and MBA degree from Columbia University.

Patrick A. Maley, Director

Patrick A. Maley has been a director of HeartSTAT Technology Inc. since September 8, 2004. He has been Chief Operating Officer of Biowave, Inc., Norwalk CT, since September 2002, and previously he served as consultant to other medical device companies since January 2002. From January 1999 to December 2001, he held the positions of Vice President of Marketing and Sales and Business Development at Maritech, Inc. Newton MA. He was Vice President of Sales and Marketing of Zoll Medical, Burlington, MA, a supplier of heart defibrillator devices between 1995 and 1998, was Vice President of Marketing during 1992-95 at Boston Scientific. Mr. Maley received his BA and MBA degrees at the University of California. He has interest in assuming a senior operating or marketing management position in the company.